Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
December 01, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
November 02, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@LillyPresented preclinical data demonstrating...
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
October 24, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
October 13, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
October 04, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor typesFHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation...
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
September 05, 2023 08:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
August 31, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease...
Foghorn Therapeutics Announces Chief Medical Officer Succession
August 08, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease...
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
August 04, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
— Initiating FHD-286 combination study in AML in the third quarter of 2023 — Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND —...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
June 28, 2023 07:00 ET
|
Foghorn Therapeutics, Inc.
- Clinical data support safety and tolerability profile of FHD-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor of BRG1/BRM - Clinical activity observed in...